

Financial news for SGNT dated on 2016-08-28: Nichi-Iko Pharmaceutical Completes Acquisition of Sagent Pharmaceuticals for \$21.75/Share in Cash

Financial news for SGNT dated on 2016-08-23: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for SGNT dated on 2016-08-23: Benzinga's Volume Movers

Financial news for SGNT dated on 2016-08-23: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for SGNT dated on 2016-08-22: S&P Dow Jones Indices Says 'Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle

Financial news for SGNT dated on 2016-08-01: Shepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash Tender Offer of \$21.75/Share to Acquire All Outstanding Shares of Sagent Pharmaceuticals,

Financial news for SGNT dated on 2016-07-18: Sagent Pharmaceuticals Announces the Launch of Amikacin Sulfate Injection, USP

Financial news for SGNT dated on 2016-07-11: Benzinga's M&A Chatter for Monday July 11, 2016

Financial news for SGNT dated on 2016-07-11: Mid-Afternoon Market Update: Crude Oil Down Over 1%; BioLife Solutions Shares Move Higher

Financial news for SGNT dated on 2016-07-11: 10 Biggest Mid-Day Gainers For Monday

Financial news for SGNT dated on 2016-07-11: Mid-Day Market Update: Dow Surges Over 100 Points; Sagent Pharmaceuticals Shares Spike Higher

Financial news for SGNT dated on 2016-07-11: RBC Capital Downgrades Sagent Pharmaceuticals to Sector Perform

Financial news for SGNT dated on 2016-07-11: Benzinga's Volume Movers

Financial news for SGNT dated on 2016-07-11: Mid-Morning Market Update: Markets Open Higher; Bank Of The Ozarks Profit Tops Views

Financial news for SGNT dated on 2016-07-11: 11 Stocks Moving In Monday's Pre-Market Session

Financial news for SGNT dated on 2016-07-11: A Peek Into The Markets: U.S. Stock Futures Rise; Alcoa Earnings In Focus

Financial news for SGNT dated on 2016-07-11: Nichi-Iko Pharmaceutical Co. to Acquire Sagent Pharmaceuticals for \$21.75/Share in Cash

Financial news for SGNT dated on 2016-06-16: The Market In 5 Minutes: Rates Remain Unchanged, But Hikes Still Loom

Financial news for SGNT dated on 2016-06-16: Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd. For \$40M

Financial news for SGNT dated on 2016-06-13: Sagent Pharmaceuticals Initiates Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter

Financial news for SGNT dated on 2016-06-10: UPDATE: Teva Says US District Court of Delaware Ruled In Favor of Co. Related to Infringement Suit Against Hetero, InnoPharma, Hospira, Sagent Pharma, Accord Healhtchare

Financial news for SGNT dated on 2016-05-03: Sagent Pharmaceuticals Sees FY16 Rev. \$325-\$365M vs. Est. \$343M

Financial news for SGNT dated on 2016-05-03: Sagent Pharmaceuticals Reports Q1 EPS \$(0.15) vs. Est \$0.01, Rev. \$67.8M vs. Est. \$74.3M

Financial news for SGNT dated on 2016-03-01: Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg Per 100mL Due to the Discovery of an Out of Specification Impurity

Financial news for SGNT dated on 2016-02-16: Sagent Pharma. Sees FY16 Rev. \$325-\$365M vs. Es.t \$347.22M

Financial news for SGNT dated on 2016-02-16: Sagent Pharmaceuticals Reports Q4 EPS \$(0.55) vs. Est. \$(0.02), Rev. \$83.108M vs. Est. \$78.13M

Financial news for SGNT dated on 2016-01-13: Benzinga's M&A Chatter for Wednesday

January 13, 2016

Financial news for SGNT dated on 2016-01-13: Sagent Pharmaceuticals Exploring Sale -Reuters

Financial news for SGNT dated on 2016-01-06: JP Morgan Initiates Coverage on Sagent Pharmaceuticals at Neutral, Announces \$20.00 PT

Financial news for SGNT dated on 2015-12-31: 8-K from Sagent Pharma Shows Co.'s Board Authorized Sale of All of Co.'s Interests in China Unit

Financial news for SGNT dated on 2015-11-03: Sagent Pharmaceuticals Sees FY15 Rev. \$305-\$330M vs. Est. \$313.71M

Financial news for SGNT dated on 2015-11-03: Sagent Pharmaceuticals Reports Q3 EPS (0.05) vs. Est. \$(0.06), Rev. \$75.2M vs. Est. \$73.84M

Financial news for SGNT dated on 2015-10-27: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Lowest PEG Ratio

Financial news for SGNT dated on 2015-09-08: MKM Partners Would Sell These Healthcare Stocks On Weaker Relative Trends

Financial news for SGNT dated on 2015-08-20: The Coming Drug-Patent Cliff Is Pushing This Portfolio Up

Financial news for SGNT dated on 2015-08-04: Sagent Pharmaceuticals Shares Spike Nearly \$1 Following Mid-Day Upgrade to Outperform from RBC

Financial news for SGNT dated on 2015-08-04: Sagent Pharmaceuticals Reports Q2 EPS \$(0.01) vs. Est. \$0.05, Rev. \$77.3M vs. Est. \$83.28M

Financial news for SGNT dated on 2015-07-28: ETFs For The Next Pharma Takeover Candidates

Financial news for SGNT dated on 2015-06-19: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years

Financial news for SGNT dated on 2015-06-16: Benzinga's Volume Movers

Financial news for SGNT dated on 2015-06-03: Analyst Knocks High-Profile Biotech Merger Battle; Opportunities Elsewhere

Financial news for SGNT dated on 2015-06-03: Raymond James Initiates Coverage on Sagent Pharmaceuticals at Strong Buy, Announces \$31.00 PT

Financial news for SGNT dated on 2015-04-13: Sagent Pharmaceuticals Launches Vancomycin Hydrochloride for Injection, USP

Financial news for SGNT dated on 2015-04-08: 2 Biotech Stocks Deutsche Bank Just Initiated

Financial news for SGNT dated on 2015-04-07: Deutsche Bank Initiates Coverage on Sagent Pharmaceuticals at Buy, Announces \$29.00 PT

Financial news for SGNT dated on 2015-03-30: 5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for SGNT dated on 2015-03-27: Porat To Google Just One Of The Week's Top Management Changes; Here Are 7 More

Financial news for SGNT dated on 2015-03-26: Oxford Industries, Orexigen And GameStop Lead Thursday's After-Hours Movers

Financial news for SGNT dated on 2015-03-26: Sagent Pharmaceutical's Jeffrey Yordon Retires As CEO; Company To Begin Search For CEO

Financial news for SGNT dated on 2015-02-23: Sagent Pharmaceutical Initiates Nationwide Voluntary Recall Following FDA Observations

Financial news for SGNT dated on 2015-02-20: 5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for SGNT dated on 2015-02-19: Sagent Pharmaceutical Reports 2015 Guidance Rev. \$325M-\$375M

Financial news for SGNT dated on 2015-02-19: Sagent Pharmaceutical Reports Q4 EPS \$0.91, \$84.4M

Financial news for SGNT dated on 2015-01-28: Morgan Stanley Sells 78,041 Shares of Sagent Pharmaceuticals @\$26.16/Share -Form 4

Financial news for SGNT dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for SGNT dated on 2015-01-13: Actavis Reports Launch of US Generic Specialty Injectable Portfolio; Says Will Immediately Begin Marketing 20 Injectable Products

Financial news for SGNT dated on 2015-01-12: Sagent Pharmaceuticals Narrows FY2014 Sales Guidance from \$250.0M-290.0M to \$275.0M-285.0M

Financial news for SGNT dated on 2015-01-12: Sagent Pharmaceuticals Sees FY2015 Sales \$325.0M-375.0M

Financial news for SGNT dated on 2015-01-09: 5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for SGNT dated on 2014-12-30: Sagent Pharma Reports Launch of Colistimethate for Injection, USP

Financial news for SGNT dated on 2014-12-29: Top 4 NASDAQ Stocks In The Drugs Generic Industry With The Highest EPS Growth Forecast For Next 5 Years

Financial news for SGNT dated on 2014-12-18: Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Lowest PEG Ratio

Financial news for SGNT dated on 2014-11-04: Sagent Pharmaceuticals, Inc. Reports Q3 EPS of \$0.08 vs \$(0.04) Est; Revenue of \$65.40M vs \$64.01M Est

Financial news for SGNT dated on 2014-10-03: Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Three Lots of Ketorolac Tromethamine Injection, USP, 30mg/mL Due to Labeling the Product With the Incorrect Expiration Date

Financial news for SGNT dated on 2014-10-02: Stocks Hitting 52-Week Highs

Financial news for SGNT dated on 2014-10-01: Sagent Pharmaceuticals Announces Acquisition of Omega Laboratories

Financial news for SGNT dated on 2014-09-26: Sagent Pharmaceuticals Launches GLYDO (Lidocaine HCl Jelly USP, 2%)

Financial news for SGNT dated on 2014-09-23: Sagent Pharmaceuticals Announces The Introduction of Oxaliplatin Injection, USP

Financial news for SGNT dated on 2014-09-17: Sagent Pharmaceuticals Announces Launch Of Ketorolac Tromethamine Injection

Financial news for SGNT dated on 2014-09-16: Stocks Hitting 52-Week Highs

Financial news for SGNT dated on 2014-09-05: Sagent Pharma Reports Launch of Ibandronate Sodium Injection

Financial news for SGNT dated on 2014-08-05: Sagent Reports Reintroduction of Irinotecan Hydrochloride Injection, USP

Financial news for SGNT dated on 2014-08-04: 5 Drug Companies Profiting From Generics

Financial news for SGNT dated on 2014-07-31: Needham Downgrades Sagent Pharmaceuticals, Inc. to Hold, Maintains \$25.00 PT

Financial news for SGNT dated on 2014-07-30: Sagent Pharmaceuticals, Inc. Reports Q2 EPS of \$0.09 vs \$(0.01) Est; Revenue of \$69.20M vs \$67.20M Est

Financial news for SGNT dated on 2014-07-25: UPDATE: Bank Of America Downgrades Sagent Pharmaceuticals On Potential Near-Term Volatility

Financial news for SGNT dated on 2014-07-25: Bank of America Downgrades Sagent Pharmaceuticals, Inc. to Neutral, Raises PO to \$28.00

Financial news for SGNT dated on 2014-06-26: Among A Raft Of Index Changes, Affiliated Managers Group To Join S&P 500

Financial news for SGNT dated on 2014-06-24: UPDATE: Sagent Will Replace LaSalle Hotel, Interpid Potash Will Replace Jakks in S&P SmallCap 600

Financial news for SGNT dated on 2014-05-06: Morning Market Movers

Financial news for SGNT dated on 2014-04-21: Jefferies Initiates Coverage on Sagent Pharmaceuticals, Inc. at Hold, Announces \$23.00 PT

Financial news for SGNT dated on 2014-04-21: Sagent Pharmaceuticals Announces the Reintroduction of Adenosine Injection, USP

Financial news for SGNT dated on 2014-04-21: Sagent Pharmaceuticals Announces Reintroduction of Adenosine Injection

Financial news for SGNT dated on 2014-03-31: Sagent Pharmaceuticals Launches Adenosine Injection

Financial news for SGNT dated on 2014-03-13: Sagent Pharmaceuticals Says Plans Spending Up to \$500M on Deal

Financial news for SGNT dated on 2014-03-04: Sagent Pharma Discloses Initiation of Nationwide Voluntary Recall of Two Lots of Zoledronic Acid Injection, 5mg/100mL, Cites Possible Lack of Container Integrity

Financial news for SGNT dated on 2014-02-21: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Financial news for SGNT dated on 2014-02-12: Morgan Stanley Sees Transition Year Ahead for Sagent Pharmaceuticals

Financial news for SGNT dated on 2014-02-12: RBC Capital Upgrades Sagent Pharmaceuticals, Inc. to Sector Perform, Lowers PT to \$20.00

Financial news for SGNT dated on 2014-02-11: Sagent Pharmaceuticals, Inc. Sees FY2014 Sales \$250.0M-290.0M vs \$282.54M Est, Sees Loss of \$10M to Net Income of \$10M

Financial news for SGNT dated on 2014-02-11: Sagent Pharmaceuticals, Inc. Reports Q4 EPS of \$0.11 vs \$(0.01) Est; Revenue of \$64.10M vs \$60.25M Est

Financial news for SGNT dated on 2014-02-07: UPDATE: Shares of Sagent Pharmaceuticals Respond to Bank of America's Upgrade

Financial news for SGNT dated on 2014-02-07: Bank of America Upgrades Sagent Pharmaceuticals, Inc. to Buy, Lowers PO to \$25.00

Financial news for SGNT dated on 2014-01-06: RBC Capital Initiates Coverage on Sagent Pharmaceuticals, Inc. at Underperform, Announces \$22.00 PT

Financial news for SGNT dated on 2013-12-23: Sagent Pharmaceuticals Announces Launch of Octreotide Acetate Injection

Financial news for SGNT dated on 2013-11-18: Sagent Pharma Reports Launch of Propofol Injectable Emulsion usp 1%

Financial news for SGNT dated on 2013-11-11: Sagent Pharmaceuticals Launches Doxorubicin Hydrochloride Injection

Financial news for SGNT dated on 2013-11-05: Sagent Pharmaceuticals, Inc. Sees FY2013 Sales \$230.0M-250.0M vs \$243.91M Est

Financial news for SGNT dated on 2013-11-05: CORRECTION: Sagent Pharmaceuticals, Inc. Reports Q3 EPS of \$0.10 vs \$(0.02) Est; Revenue of \$60.80M vs \$60.82M Est

Financial news for SGNT dated on 2013-09-11: RBC Capital Upgrades Sagent Pharmaceuticals, Inc. to Outperform, Raises PT to \$25.00

Financial news for SGNT dated on 2013-09-10: Sagent Pharmaceuticals Prices 4.6M Share Offering at \$21.25/Share

Financial news for SGNT dated on 2013-09-09: Market Wrap for Monday, September 9: Nasdaq Bounces To 13 Year High

Financial news for SGNT dated on 2013-09-09: Mid-Afternoon Market Update: Markets Lead by the NASDAQ as Various Health Names Drop

Financial news for SGNT dated on 2013-09-09: Mid-Day Market Update: Dow Rises Over 100 Points; Apple Shares Gain

Financial news for SGNT dated on 2013-09-09: Mid-Morning Market Update: Markets Open Higher; Koch Industries To Acquire Molex For \$38.50/Share

Financial news for SGNT dated on 2013-09-09: Sagent Pharmaceuticals Announces 4.441M Share Offering

Financial news for SGNT dated on 2013-08-06: Sagent Pharma Narrows FY13 Sales Guidance from \$220-250M to \$230-250M vs \$246M Est.

Financial news for SGNT dated on 2013-08-06: Sagent Pharmaceuticals, Inc. Reports Q2 EPS of \$0.46 Which May Not Compare \$(0.01) Est; Revenue of \$59.60M Which May Not Compare \$59.27M Est

Financial news for SGNT dated on 2013-08-05: Sagent Pharma Reports Reintroduction of Amiodarone HCL Injection

Financial news for SGNT dated on 2013-07-31: Sagent Pharmaceuticals Launches Docetaxel Injection Concentrate

Financial news for SGNT dated on 2013-07-03: UPDATE: Bank of America Raises PT on Sagent Pharmaceuticals on Higher Sales Estimates

Financial news for SGNT dated on 2013-06-13: Sagent Pharma Expands Nationwide Recall of All Lots of Vecuronium Bromide for Injection, 10mg

Financial news for SGNT dated on 2013-06-07: Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Three Lots of Vecuronium Bromide for Injection

Financial news for SGNT dated on 2013-05-06: Sagent Pharmaceuticals, Inc. Reports Q1 EPS of \$0.34 Which May Not Compare \$(0.03) Est; Revenue of \$60.20M

Financial news for SGNT dated on 2013-05-06: Sagent Pharmaceuticals to Acquire Remaining 50% Interest in Kanghong Sagent Pharmaceutical JV for \$25M

Financial news for SGNT dated on 2013-03-19: Sagent Pharma Names James Hussey President

Financial news for SGNT dated on 2013-03-05: Sagent Pharma Reports Approval, Launch of Zoledronic Acid Injection 4 mg in Plastic Vial

Financial news for SGNT dated on 2013-02-19: Jefferies Maintains Buy on Sagent Pharmaceuticals, Inc., Lowers PT to \$20.00

Financial news for SGNT dated on 2013-02-15: UPDATE: Piper Jaffray Upgrades Sagent Pharmaceuticals to Overweight on Turnaround Outlook

Financial news for SGNT dated on 2013-02-15: Piper Jaffray Upgrades Sagent Pharmaceuticals, Inc. to Overweight, Raises PT to \$22.00

Financial news for SGNT dated on 2013-02-14: Sagent Pharmaceuticals, Inc. Sees FY2013 Sales \$220.0M-250.0M vs \$243.50M Est

Financial news for SGNT dated on 2013-02-14: Sagent Pharmaceuticals, Inc. Reports Q4 EPS of \$0.00 vs \$(0.20) Est; Revenue of \$53.20M vs \$51.33M Est

Financial news for SGNT dated on 2013-01-09: Sagent Pharma Announces Temporary Importation of Sodium Bicarbonate Injection

Financial news for SGNT dated on 2013-01-02: Sagent Pharma to Launch Flumazenil Injection, USP

Financial news for SGNT dated on 2012-12-31: Morgan Stanley Reiterates Equal-Weight Rating on Sagent Pharmaceuticals

Financial news for SGNT dated on 2012-12-21: Sagent Pharma Registers 24M Common Shares: May Offer Up to 9M Shares, May Add Another 15M Shares

Financial news for SGNT dated on 2012-11-28: Sagent Pharma Launches Nafcillin for Injection, USP

Financial news for SGNT dated on 2012-11-08: From Earlier: Sagent Pharmaceuticals Reports Q3 EPS \$-0.13 vs \$-0.20 Est; Revenues \$49.4M vs \$48.60M Est

Financial news for SGNT dated on 2012-08-13: UPDATE: Morgan Stanley Downgrades Sagent Pharmaceuticals to Equal-Weight

Financial news for SGNT dated on 2012-08-13: Morgan Stanley Downgrades Sagent Pharmaceuticals from Overweight to Equal-weight, Removes PT

Financial news for SGNT dated on 2012-08-09: Bank of America Maintains Sagent Pharmaceuticals at Neutral, Lowers PO from \$23 to \$19

Financial news for SGNT dated on 2012-08-09: Sagent Guides FY Loss \$20-30M, Had Seen \$5M; Guides FY Revenue \$180-200M, Had Seen \$220-250M vs \$221M Est

Financial news for SGNT dated on 2012-08-09: Sagent Pharmaceuticals Reports Q2 EPS \$-0.17 vs \$-0.26 Est; Revenues \$42.7M vs \$39.69M Est

Financial news for SGNT dated on 2012-08-09: Sagent Pharmaceuticals Resumes Trading

Financial news for SGNT dated on 2012-08-09: PREVIEW: Sagent Pharmaceuticals to Resume Trading at 7:30am

Financial news for SGNT dated on 2012-08-09: Sagent Pharmaceuticals Reports Second Quarter 2012 Financial Results

Financial news for SGNT dated on 2012-08-09: Sagent Pharmaceuticals Halted Pending News

Financial news for SGNT dated on 2012-08-01: Jefferies & Company Maintains Sagent Pharmaceuticals at Buy, Lowers PT from \$28 to \$23

Financial news for SGNT dated on 2012-07-24: Sagent Pharmaceuticals Announces Launch of Oxacillin for Injection, USP

Financial news for SGNT dated on 2012-05-18: Sagent Pharmaceuticals Announces Launch of Atracurium Besylate Injection

Financial news for SGNT dated on 2012-05-17: Sagent Pharmaceuticals Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials

Financial news for SGNT dated on 2012-05-14: UPDATE: Morgan Stanley Cuts PT to \$27 on Sagent Pharmaceuticals; Progress Amid Soft Q1

Financial news for SGNT dated on 2012-05-14: Morgan Stanley Maintains Sagent Pharmaceuticals at Overweight, Lowers PT from \$28 to \$27

Financial news for SGNT dated on 2012-05-11: Bank of America Maintains Sagent Pharmaceuticals at Neutral, Lowers PO from \$24 to \$23

Financial news for SGNT dated on 2011-11-29: Collins Stewart Initiates Coverage on Sagent Pharmaceuticals

Financial news for SGNT dated on 2011-11-29: Collins Stewart Initiates Coverage on Sagent Pharma at Buy, \$25 PT

Financial news for SGNT dated on 2011-11-01: Morgan Stanley Overweight on Sagent Pharmaceuticals

Financial news for SGNT dated on 2011-10-03: J.P. Morgan Neutral on Sagent Pharmaceuticals

Financial news for SGNT dated on 2011-09-28: J.P. Morgan Initiates Coverage on Sagent Pharmaceuticals with a Neutral Rating

Financial news for SGNT dated on 2011-09-28: JP Morgan Initiates Sagent Pharmaceuticals at Neutral, \$25 PT

Financial news for SGNT dated on 2011-09-27: Sagent Pharmaceuticals Launches Paclitaxel Injection, USP

Financial news for SGNT dated on 2011-09-06: FDA Approves Sagent Pharmaceuticals' Haloperidol Injection, USP

Financial news for SGNT dated on 2011-09-06: FDA Approves Sagent Pharmaceuticals' Haloperidol Injection, USP

Financial news for SGNT dated on 2011-08-25: Sagent Pharmaceuticals Names Jonathon Singer Chief Financial Officer

Financial news for SGNT dated on 2011-08-18: Sagent Pharmaceuticals Launches Vecuronium Bromide For Injection

Financial news for SGNT dated on 2011-08-10: UPDATE: Jefferies Lowers PT on Sagent Pharmaceuticals to \$28

Financial news for SGNT dated on 2011-08-10: Morgan Stanley Trims Estimates On Sagent Pharmaceuticals

Financial news for SGNT dated on 2011-08-10: Jefferies Lowers PT on Sagent Pharmaceuticals To 428

Financial news for SGNT dated on 2011-08-10: Morgan Stanley Lowers PT On Sagent Pharmaceuticals To \$29

Financial news for SGNT dated on 2011-07-11: Sagent Pharmaceuticals and Chongqing Lummy Pharmaceutical Company Announce Development Collaboration

Financial news for SGNT dated on 2011-07-08: Jefferies Retains Buy Rating On Sagent

Financial news for SGNT dated on 2011-07-07: Sagent Pharmaceuticals Launches Levofloxacin Injection, the Generic Form of Levaquin in Premix Bags

Financial news for SGNT dated on 2011-06-21: Morgan Stanley Provides Color on Sagent Pharmaceuticals, Overweight

Financial news for SGNT dated on 2011-06-03: Jefferies' Updates 6/3

Financial news for SGNT dated on 2011-06-03: UPDATE: Jefferies Initiates Sagent Pharmaceuticals at Buy

Financial news for SGNT dated on 2011-06-03: Jefferies Initiates Sagent Pharmaceuticals At Buy, \$31 PT

Financial news for SGNT dated on 2011-05-31: Bank of America Merrill Lynch Initiates Coverage on Sagent Pharmaceuticals

Financial news for SGNT dated on 2011-05-31: Bank of America Initiates Sagent Pharmaceuticals At Neutral, \$27 PO

Financial news for SGNT dated on 2011-05-24: Sagent Pharmaceuticals Plans Launch of Piperacillin and Tazobactam, the Generic Form of Zosyn, for Injection

Financial news for SGNT dated on 2011-04-26: Sagent Pharmaceuticals Announces Closing of 5.75M Share IPO

Financial news for SGNT dated on 2011-04-20: Sagent Pharma IPO Begins Trading Higher After Priced At \$16 (SGNT)

Financial news for SGNT dated on 2011-04-06: Sagent Pharmaceuticals Announces IPO